Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10279602 | 0.92 | SMO (0.62) | SMOKCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL401175 | 0.92 | SMO (0.61) | SMOKCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL4973233 | 0.90 | SMO (0.60) | SMOKCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL401379 | 0.88 | SMO (0.72) | SMORAB9ANPC1KCNQ3KCNQ2 | |
| SCHEMBL403314 | 0.87 | SMO (0.71) | SMORAB9ANPC1KCNQ3KCNQ2 | |
| SCHEMBL12832029 | 0.87 | SMO (0.77) | SMORAB9ANPC1KCNQ3KCNQ2 | |
| SCHEMBL3679282 | 0.87 | P4HTM (0.58) | SMOKCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL403550 | 0.87 | HDAC2 (0.64) | SMOKCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL402516 | 0.86 | SMO (0.70) | SMORAB9ANPC1MAPTLMNA | |
| SCHEMBL402586 | 0.86 | SMO (0.67) | SMORAB9ANPC1DYRK1AKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | claimed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | claimed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | SHH, GLI1, SMO | SMO 3/4885KCNH2 2806/4885HDAC2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.